Salvage treatment in prostate cancer: A clinical approach

Expert Review of Anticancer Therapy

Volumn 13, Issue 5, 2013, Pages 613-623

  Bjerklund Johansen, Truls E ^a   Witzsch, Ulrich ^b   Greene, Damian ^c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b KRANKENHAUS NORDWEST   (Germany)

^c SUNDERLAND ROYAL HOSPITAL   (United Kingdom)

Author keywords

benefits; salvage cryoablation; salvage HIFU; salvage prostatectomy; salvage radiotherapy; side effects

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER RADIOTHERAPY; COMPARATIVE STUDY; CRYOSURGERY; EXTERNAL BEAM RADIOTHERAPY; HEALTH HAZARD; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; MULTICENTER STUDY (TOPIC); PATIENT SELECTION; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; SALVAGE THERAPY; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME;

CRYOSURGERY; HIGH-INTENSITY FOCUSED ULTRASOUND ABLATION; HUMANS; MALE; PATIENT SELECTION; PROSTATECTOMY; PROSTATIC NEOPLASMS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84876849429     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.13.35     Document Type: Article

References (63)

1. Kimura M, Mouraviev V, Tsivian M, Mayes JM, Satoh T, Polascik TJ. Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy. BJU Int. 105(2), 191-201 (2010).
2. Keane T, Gillatt D, Lawton C, Payne H, Tombal B. Treatment options in prostate cancer once primary therapy fails. Eur. Urol. 6(Suppl. 3), 344-353 (2007).
3. Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR; Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE). Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer 112(2), 307-314 (2008).
4. Nguyen PL, D'Amico AV, Lee AK, Suh WW. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer 110(7), 1417-1428 (2007).
5. Srigley JR, Delahunt B, Evans AJ. Therapyassociated effects in the prostate gland. Histopathology 60(1), 153-165 (2012).
6. Carlsson S, Bratt O, Stattin P, Egevad L. Current routines for transrectal ultrasoundguided prostate biopsy: a web-based survey by the Swedish Urology Network. Scand. J. Urol. Nephrol. 46(6), 405-410 (2012).
7. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason M. Neo-Adjuvant Hormone Therapy for Localized and Locally Advanced Prostate Cancer (Review) The Cochrane Library. The Cochrane Collaboration. John Wiley & Sons Ltd, Chichester, UK (2009).
8. Eastham JA, Kuroiwa K, Ohori M et al. Prognostic significance of location of positive margins in radical prostatectomy specimens. Urology 70(5), 965-969 (2007).
9. Heidenreich A, Bolla M, Joniau S et al. Guidelines on Prostate Cancer. Eur. Assoc. Urol. February 2012.
10. Warmuth M, Johansson T, Mad P. Systematic review of the efficacy and safety of high-intensity focussed ultrasound for the primary and salvage treatment of prostate cancer. Eur. Urol. 58(6), 803-815 (2010).
11. Peinemann F, Grouven U, Bartel C et al. Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials. Eur. Urol. 60(5), 881-893 (2011).
12. Yossepowitch O, Bjartell A, Eastham JA et al. Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences. Eur. Urol. 55(1), 87-99 (2009).
13. Briganti A, Wiegel T, Joniau S et al. Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. Eur. Urol. 62(3), 472-487 (2012).
14. Poortmans P, Bossi A, Vandeputte K et al.; EORTC Radiation Oncology Group. Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother. Oncol. 84(2), 121-127 (2007).
15. Khan MA, Han M, Partin AW, Epstein JI, Walsh PC. Long-term cancer control of radical prostatectomy in men younger than years of age: update 2003. Urology 62(1), 86-91; discussion 91 (2003).
16. Leventis AK, Shariat SF, Slawin KM. Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. Radiology 219(2), 432-439 (2001).
17. Choo R, Hruby G, Hong J et al. (IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy. Int. J. Radiat. Oncol. Biol. Phys. 53(2), 269-276 (2002).
18. Witzsch U, Hieronymi S, Voss G, Becht E. Salvage cryoablation of prostate cancer using 17 gauge cryoneedles is a local option after radical prostatectomy failure! Eur. Urol. Suppl. 10(2), 92 (2011).
19. Gomez-Veiga F, Mariño A, Alvarez L et al. Brachytherapy for the treatment of recurrent prostate cancer after radiotherapy or radical prostatectomy. BJU Int. 109(Suppl. 1), 17-21 (2012).
20. Nilsson S, Norlén BJ, Widmark A. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol. 43(4), 316-381 (2004).
21. Grossfeld GD, Li YP, P Lubeck DP, Carroll PR. Patterns of failure after primary local therapy for prostate cancer and rationale for secondary therapy. Urology 60(3 Suppl. 1), 57-62; discussion 62 (2002).
22. Lawrentschuk N, Finelli A, Van der Kwast TH et al. Salvage radical prostatectomy following primary high intensity focused ultrasound for treatment of prostate cancer. J. Urol. 185(3), 862-868 (2011).
23. Riviere J, Bernhard JC, Robert G et al. Salvage radiotherapy after high-intensity focussed ultrasound for recurrent localised prostate cancer. Eur. Urol. 58(4), 567-573 (2010).
24. Mouraviev V, Spiess PE, Jones JS. Salvage cryoablation for locally recurrent prostate cancer following primary radiotherapy. Eur. Urol. 61(6), 1204-1211 (2012).
25. Heidenreich A, Richter S, Thüer D, Pfister D. Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. Eur. Urol. 57(3), 437-443 (2010).
26. Loeb S, Schaeffer EM, Trock BJ, Epstein JI, Humphreys EB, Walsh PC. What are the outcomes of radical prostatectomy for high-risk prostate cancer? Urology 76(3), 710-714 (2010).
27. Gorin MA, Manoharan M, Shah G, Eldefrawy A, Soloway MS. Salvage open radical prostatectomy after failed radiation therapy: a single center experience. Central Eur. J. Urol. 64(3), 144-147 (2011).
28. Paparel P, Cronin AM, Savage C, Scardino PT, Eastham JA. Oncologic outcome and patterns of recurrence after salvage radical prostatectomy. Eur. Urol. 55(2), 404-410 (2009).
29. Williams AK, Martínez CH, Lu C, Ng CK, Pautler SE, Chin JL. Disease-free survival following salvage cryotherapy for biopsy-proven radio-recurrent prostate cancer. Eur. Urol. 60(3), 405-410 (2011).
30. Ismail M, Ahmed S, Kastner C, Davies J. Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. BJU Int. 100(4), 760-764 (2007).
31. Pisters LL, Rewcastle JC, Donnelly BJ, Lugnani FM, Katz AE, Jones JS. Salvage prostate cryoablation: initial results from the cryo on-line data registry. J. Urol. 180(2), 559-563; discussion 563 (2008).
32. Murat FJ, Poissonnier L, Rabilloud M et al. Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. Eur. Urol. 55(3), 640-647 (2009).
33. Berge V, Baco E, Karlsen SJ. A prospective study of salvage high-intensity focused ultrasound for locally radiorecurrent prostate cancer: early results. Scand. J. Urol. Nephrol. 44(4), 223-227 (2010).
34. Bolla M, van Poppel H, Collette L et al.; European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366(9485), 572-578 (2005).
35. Thompson IM, Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J. Urol. 181(3), 956-962 (2009).
36. Wiegel T, Bottke D, Steiner U et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J. Clin. Oncol. 27(18), 2924-2930 (2009).
37. Stephenson AJ, Bolla M, Briganti A et al. Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur. Urol. 61(3), 443-451 (2012).
38. King CR. The timing of salvage radiotherapy after radical prostatectomy: a systematic review. Int. J. Radiat. Oncol. Biol. Phys. 84(1), 104-111 (2012).
39. Thompson IM Jr, Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296(19), 2329-2335 (2006).
40. Dov K. Radiation therapy after radical prostatectomy: strike early, strike hard! The case for adjuvant radiation therapy. Rev. Urol. 4(2), 87-89 (2002).
41. Chin JL. Salvage versus adjuvant radiotherapy after radical prostatectomy: argument for adjuvant radiotherapy. CUAJ 3(3), 241-244 (2009).
42. Chade DC, Shariat SF, Cronin AM et al. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur. Urol. 60(2), 205-210 (2011).
43. Grado GL, Collins JM, Kriegshauser JS et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 53(1), 2-10 (1999).
44. Burri RJ, Stone NN, Unger P, Stock RG. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 77(5), 1338-1344 (2010).
45. Aaronson DS, Yamasaki I, Gottschalk A et al. Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy. BJU Int. 104(5), 600-604 (2009).
46. Moman MR, van der Poel HG, Battermann JJ, Moerland MA, van Vulpen M. Treatment outcome and toxicity after salvage 125-I implantation for prostate cancer recurrences after primary 125-I implantation and external beam radiotherapy. Brachytherapy 9(2), 119-125 (2010).
47. Ward JF, Sebo TJ, Blute ML, Zincke H. Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J. Urol. 173(4), 1156-1160 (2005).
48. Crook JM, Malone S, Perry G et al. Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival: results from a Canadian randomized trial. Cancer 115(3), 673-679 (2009).
49. Giovacchini G, Picchio M, Briganti A et al. [11C]choline positron emission tomography/ computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging. J. Urol. 184(3), 938-943 (2010).
50. Pucar D, Shukla-Dave A, Hricak H et al. Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology 236(2), 545-553 (2005).
51. Azoulay L, Yin H, Benayoun S, Renoux C, Boivin JF, Suissa S. Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer. Eur. Urol. 60(6), 1244-1250 (2011).
52. Fowler FJ Jr, Barry MJ, Lu-Yao G, Wasson JH, Bin L. Outcomes of external-beam radiation therapy for prostate cancer: a study of Medicare beneficiaries in three surveillance, epidemiology, and end results areas. J. Clin. Oncol. 14(8), 2258-2265 (1996).
53. Donnelly BJ, Saliken JC, Brasher PM et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer 116(2), 323-330 (2010).
54. Jones JS. Radiorecurrent prostate cancer: an emerging and largely mismanaged epidemic. Eur. Urol. 60, 411-412 (2011).
55. Schröder FH, Hugosson J, Roobol MJ et al.; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360(13), 1320-1328 (2009).
56. Bolla M, van Poppel H, Collette L et al.; European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366(9485), 572-578 (2005).
57. Geinitz H, Riegel MG, Thamm R et al. Outcome after conformal salvage radiotherapy in patients with rising prostate-specific antigen levels after radical prostatectomy. Int. J. Radiat. Oncol. Biol. Phys. 82(5), 1930-1937 (2012).
58. Stephenson AJ, Scardino PT, Bianco FJ Jr, DiBlasio CJ, Fearn PA, Eastham JA. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. J. Urol. 172(6 Pt 1), 2239-2243 (2004).
59. Ward JF, Sebo TJ, Blute ML, Zincke H. Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J. Urol. 173(4), 1156-1160 (2005).
60. Langenhuijsen JF, Broers EM, Vergunst H. Cryosurgery for prostate cancer: an update on clinical results of modern cryotechnology. Eur. Urol. 55(1), 76-86 (2009).
61. Gheiler EL, Tefilli MV, Tiguert R et al. Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. Urology 51(5), 789-795 (1998).
62. American Urological Association. Best Practice Policy Statement on: Cryosurgery for the Treatment of Localized Prostate Cancer (2008). www.auanet.org/content/guidelines-andquality-care/clinical-guidelines.cfm
63. National Health Service. National Institute for Health Research Cancer Research Network (NCRN). www.ncrn.org.uk